26.57

1.53% 0.40

Pre-market: 26.55 -0.02 -0.08%

Beam Therapeutics Inc (BEAM)

Overview News Price History Option Chain Financials Why BEAM Down? Discussions Forecast

Beam Therapeutics Inc stock is traded at $26.57, with a volume of 3.21M. It is up +1.53% in the last 24 hours and up +26.64% over the past month. Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Previous Close:

$26.17

Open:

$26.4

24h Volume:

3.21M

Relative Volume:

1.42

Market Cap:

$2.70B

Revenue:

$352.57M

Net Income/Loss:

$-143.01M

P/E Ratio:

-14.68

EPS:

-1.81

Net Cash Flow:

$-153.40M

1W Performance:

-2.89%

1M Performance:

+26.64%

6M Performance:

+56.39%

1Y Performance:

-1.04%

1-Day Range:

$26.30

$27.16

1-Week Range:

$25.53

$28.10

52-Week Range:

$13.53

$35.25

Beam Therapeutics Inc Stock (BEAM) Company Profile

Name

Beam Therapeutics Inc

Sector

Healthcare (1133)

Industry

Biotechnology (633)

Phone

857-327-8775

Address

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Employee

510

Twitter

Next Earnings Date

2024-11-05

Latest SEC Filings

BEAM's Discussions on Twitter

Compare BEAM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BEAM Beam Therapeutics Inc	26.57	2.66B	352.57M	-143.01M	-153.40M	-1.81
VRTX Vertex Pharmaceuticals Inc	456.20	113.51B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	767.96	78.69B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	400.23	52.32B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	854.99	52.15B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	174.84	35.52B	447.02M	-1.18B	-906.14M	-6.1812

Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-09-25	Initiated	Jefferies	Buy
Mar-28-25	Upgrade	BofA Securities	Neutral → Buy
Mar-10-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform
Jan-29-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-06-24	Upgrade	Leerink Partners	Market Perform → Outperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jul-23-24	Initiated	H.C. Wainwright	Buy
Jan-29-24	Upgrade	JP Morgan	Neutral → Overweight
Dec-15-23	Downgrade	BofA Securities	Buy → Neutral
Dec-08-23	Downgrade	Jefferies	Buy → Hold
Oct-20-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-20-23	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-21-23	Initiated	Bernstein	Mkt Perform
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight
Dec-20-22	Upgrade	BMO Capital Markets	Market Perform → Outperform
Dec-13-22	Initiated	Citigroup	Buy
Jun-17-22	Initiated	BMO Capital Markets	Market Perform
Apr-28-22	Initiated	Credit Suisse	Neutral
Jan-05-22	Initiated	Guggenheim	Buy
Oct-19-21	Initiated	SVB Leerink	Outperform
Sep-24-21	Resumed	Stifel	Buy
Sep-10-21	Initiated	BofA Securities	Buy
May-11-21	Initiated	Redburn	Buy
May-04-21	Initiated	RBC Capital Mkts	Sector Perform
Mar-01-21	Downgrade	Barclays	Overweight → Equal Weight
Feb-16-21	Initiated	Wells Fargo	Overweight
Jan-29-21	Downgrade	JP Morgan	Overweight → Neutral
Jan-06-21	Initiated	Stifel	Hold
Aug-05-20	Initiated	William Blair	Outperform
Mar-02-20	Initiated	Barclays	Overweight
Mar-02-20	Initiated	JP Morgan	Overweight
Mar-02-20	Initiated	Jefferies	Buy
Mar-02-20	Initiated	Wedbush	Outperform

View All

Beam Therapeutics Inc Stock (BEAM) Latest News

Dec 20, 2025

Growth Value: Will Beam Therapeutics Inc. stock benefit from infrastructure spending2025 Price Action Summary & Short-Term High Return Strategies - ulpravda.ru

Dec 20, 2025

Will Beam Therapeutics Inc. stock benefit from infrastructure spendingSector Performance Drivers & Actionable Entry & Exit Points Daily - Bollywood Helpline

Dec 20, 2025

Targets Report: What margin trends mean for Beam Therapeutics Inc. stockPortfolio Performance Report & Expert Approved Trade Ideas - ulpravda.ru

Dec 20, 2025

Dec 19, 2025

Growth Report: Is Beam Therapeutics Inc. stock attractive for retirement portfoliosJuly 2025 Technicals & Reliable Entry Point Alerts - ulpravda.ru

Dec 19, 2025

Will Beam Therapeutics Inc. stock reach all time highs in 20252025 Buyback Activity & Low Risk High Win Rate Picks - DonanımHaber

Dec 19, 2025

Will Beam Therapeutics Inc. stock beat EPS estimatesCEO Change & Capital Protection Trading Alerts - DonanımHaber

Dec 19, 2025

Is Beam Therapeutics Inc. stock cheap compared to fundamentalsMarket Growth Report & Short-Term High Return Strategies - Улправда

Dec 19, 2025

Dec 18, 2025

Price-Driven Insight from (BEAM) for Rule-Based Strategy - news.stocktradersdaily.com

Dec 18, 2025

Aug Final Week: Is Beam Therapeutics Inc. stock a defensive play in 2025July 2025 EndofMonth & Free Community Consensus Stock Picks - ulpravda.ru

Dec 18, 2025

Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire

Dec 18, 2025

What margin trends mean for Beam Therapeutics Inc. stockEarnings Risk Summary & Reliable Volume Spike Alerts - ulpravda.ru

Dec 18, 2025

Is Beam Therapeutics Inc. stock a defensive play in 20252025 Market WrapUp & Long Hold Capital Preservation Tips - Улправда

Dec 18, 2025